OakChart

Alpha Tau Medical Ltd

DRTSHealthcare·Biotechnology·Israel·Small·NASD·Nov 11 • 2:51 PM ET

14.16+0.46 (3.36%)
2026-11-11 20:51 CET
Market cap
1,266.95 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-92.57 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-1.04
P/E
-
Compare

Price

DRTS against its 20, 50 and 200-day averages
2050200earnings
5.007.5010.0012.5015.002.5M4.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26DRTSclose 14.1620-day 13.3150-day 14.11200-day 10.8614.1652w high

10.3% under the 52-week high of 15.79 on 17 Sep 2026. 52-week low 3.43 on 21 Nov 2025. Last 15 sessions, 15.2% high to low

Profile

DRTS
52-week range, 87% of the way up
3.4315.79

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Employees112
IPOMar 08, 2021
Beta1.28
ATR, 14d0.69
Rel volume1.51
Short float5.29%
Insider own19.81%
Inst own9.30%

Snapshot

6 groups

Valuation

Index-
Market Cap1.31B
Enterprise Value1.22B
Income-92.57M
Sales0.00M
Book/sh0.48
Cash/sh1.13
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees112
IPOMar 08, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B29.68
P/C12.50
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio11.09
Current Ratio11.09
Debt/Eq0.34
LT Debt/Eq0.31
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.04
EPS next Y-0.54
EPS next Q-0.15
EPS this Y-82.12%
EPS next Y44.10%
EPS next 5Y4.92%
EPS past 3/5Y0.15% -19.21%
Sales past 3/5Y- -
EPS Y/Y TTM-115.15%
Sales Y/Y TTM-
EPS Q/Q-301.43%
Sales Q/Q-
EarningsAug 10 AMC
EPS/Sales Surpr.-256.14% -98.27%

Ownership

Insider Own19.81%
Insider Trans-0.72%
Inst Own9.30%
Inst Trans12.85%
ROA-75.51%
ROE-141.68%
ROIC-159.91%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA206.41%
SMA500.35%
SMA20030.37%
Trades-

Technical

Shs Outstand92.33M
Shs Float74.16M
Short Float5.29%
Short Ratio7.24
Short Interest3.92M
52W High15.79 -10.32%
52W Low3.43 312.83%
Volatility5.48% 5.08%
ATR (14)0.69
RSI (14)54.69
Beta1.28
Rel Volume1.51
Avg Volume541.33K
Volume679,491

Performance

Perf Week0.93%
Perf Month3.06%
Perf Quarter-2.34%
Perf Half Y46.89%
Perf YTD186.06%
Perf Year259.39%
Perf 3Y356.77%
Perf 5Y42.74%
Perf 10Y-
Recom1.20
Target Price20.60
Prev Close13.70
Price14.16
Change %3.36%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
TodayUpgradePPiper SandlerNeutral → Overweight$8 → $22+55.4%
TodayResumedPPiper SandlerOverweight
May 28, 2026InitiatedBBarclaysOverweight$15+5.9%
Mar 04, 2026DowngradePPiper SandlerOverweight → Neutral$5-64.7%
Dec 15, 2023InitiatedCCitigroupBuy$8-43.5%
Apr 24, 2023InitiatedHH.C. WainwrightBuy$9-36.4%
Apr 14, 2022InitiatedCCantor FitzgeraldOverweight$20+41.2%
Apr 08, 2022InitiatedPPiper SandlerOverweight$19+34.2%
Apr 04, 2022InitiatedCCitigroupBuy$21+48.3%

Peers

Mkt cap
TickerCompanyMkt cap
NBTXNanobiotix ADR1.68B
TLXTelix Pharmaceuticals Ltd ADR3.30B
ATNMActinium Pharmaceuticals Inc49.99M
BCAXBicara Therapeutics Inc706.36M
CGONCg Oncology Inc6.56B
RADXRadiopharm Theranostics Ltd ADR12.87M
LNTHLantheus Holdings Inc6.64B
ARAYAccuray Inc10.00M
NVSNovartis AG ADR292.92B
ICCMIcecure Medical Ltd2.63M

Insider trading

latest 14 of 29
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Levy RaphiChief Financial OfficerAug 21 '26Option Exercise2.982,8718,55693,051Aug 25 10:34 AM
Levy RaphiChief Financial OfficerAug 21 '26Sale15.002,87143,07390,180Aug 25 10:34 AM
Raphael (Raphi) Aryeh LevyOfficerAug 21 '26Proposed Sale14.365,00071,800Aug 21 05:00 PM
Levy RaphiChief Financial OfficerAug 11 '26Option Exercise2.9817,73052,835107,910Aug 12 12:18 PM
Levy RaphiChief Financial OfficerAug 11 '26Sale14.0017,730248,27790,180Aug 12 12:18 PM
Levy RaphiChief Financial OfficerJul 06 '26Option Exercise2.982,2706,76592,450Jul 07 07:49 AM
Levy RaphiChief Financial OfficerJul 06 '26Sale14.002,27031,78290,180Jul 07 07:49 AM
Levy RaphiOfficerJul 06 '26Proposed Sale13.2320,000264,600Jul 06 11:55 AM
Levy RaphiChief Financial OfficerJul 02 '26Option Exercise2.9817,87353,262108,053Jul 06 11:37 AM
Levy RaphiChief Financial OfficerJul 02 '26Sale13.0017,873232,39790,180Jul 06 11:37 AM
Levy RaphiChief Financial OfficerJul 01 '26Option Exercise2.982,1276,33892,307Jul 02 11:45 AM
Levy RaphiChief Financial OfficerJul 01 '26Sale13.022,12727,69190,180Jul 02 11:45 AM
Levy RaphiOfficerJul 01 '26Proposed Sale12.5820,000251,600Jul 02 06:32 AM
Levy RaphiChief Financial OfficerJun 30 '26Sale12.0020,000240,04490,180Jul 01 08:21 AM

Held by

AUM
TickerCompanyAUM
IEFAiShares Core MSCI EAFE ETFAUM: 191.66B
SCZiShares MSCI EAFE Small-Cap ETFAUM: 12.92B
IZRLARK Israel Innovative Technology ETFAUM: 118.95M
EISiShares MSCI Israel ETFAUM: 830.45M
IXUSiShares Core MSCI Total International Stock ETFAUM: 57.59B
GWXState Street SPDR S&P International Small Cap ETFAUM: 906.57M
ONEQFidelity Nasdaq Composite Index ETFAUM: 10.35B
EHLSEven Herd Long Short ETFAUM: 53.35M
IDEViShares Core MSCI International Developed Markets ETFAUM: 34.12B
AVSDAvantis Responsible International Equity ETFAUM: 379.33M

News

latest 14 of 198

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-10-0.502-0.141-0.000.144
2026Q12026-05-18-0.260-0.124-0.2560.000.054
2025Q42026-03-09-0.138-0.121-0.1420.000.004
2025Q32025-11-20-0.147-0.111-0.1370.000.002
2025Q22025-08-11-0.130-0.111-0.1260.000.003
2025Q12025-05-19-0.120-0.123-0.1230.000.034
2024Q42025-03-12-0.142-0.130-0.1350.000.001
2024Q32024-11-19-0.100-0.120-0.0990.000.004
2024Q22024-08-14-0.109-0.115-0.1060.000.002
2024Q12024-05-20-0.110-0.127-0.1150.000.004
2023Q42024-03-07-0.108-0.118-0.1060.000.004
2023Q32023-11-16-0.310-0.120-0.0710.000.003
2023Q22023-08-28-0.130-0.128-0.1250.000.004
2023Q12023-05-23-0.120-0.110-0.1180.000.005
2022Q42023-03-09-0.050--0.0490.00-4
2022Q32022-11-22-0.040-0.116-0.0380.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-0.670-0.260-0.6730.000.00
2022FY-0.530-0.569-0.5310.000.00
2023FY-0.420-0.432-0.4200.000.00
2024FY-0.452-0.450-0.4540.000.00
2025FY-0.529-0.510-0.000.00
2026FY--0.963--0.38
2027FY--0.539--10.72
2028FY--0.455--61.32
2029FY--0.075--126.04
2030FY-0.905--296.12

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-104020.130.000.50
2026Q3S2026-09-074010.240.000.50
2026Q3S2026-08-114000.370.001.00
2026Q3S2026-08-104000.370.001.00
2026Q3S2026-05-194000.370.001.00
2026Q3S2026-05-174000.370.001.00
2026Q3S2026-03-104100.370.001.00
2026Q3S2026-03-033100.490.001.00
2026Q3S2026-02-143000.440.001.00
2026Q3S2025-12-013010.440.001.00
2026Q3S2025-11-213001.040.002.80
2026Q3S2025-11-202001.400.002.80
2026Q3S2025-11-113001.040.002.80
2026Q3S2025-11-103001.040.002.80

Estimate history

EPS, annual-0.22-0.673-0.531-0.42-0.454-0.529-1.0398
Period202020212022202320242025TTM
EPS, quarterly-0.106-0.099-0.135-0.123-0.126-0.137-0.142-0.256-0.505
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000
Period202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual40.43440.52969.10569.67170.38188.0192.333
Period202020212022202320242025MRQ
Shares, quarterly69.92470.05270.38170.51185.04385.26488.0190.17692.333
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue0.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.001.231.101.070.980.780.09
Gross Profit0.00-1.23-1.10-1.07-0.98-0.78-0.09
Selling, General and Administrative Excl. Other50.4341.0634.9434.6131.1613.019.16
Research and Development38.7730.8327.0226.4220.8910.677.46
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-50.43-42.29-36.04-35.68-32.14-13.79-9.24
Interest Expense-0.420.340.040.0213.270.22
Unusual Expense0.002.02-0.26-2.033.790.000.00
Net Income Before Taxes-92.40-42.51-31.74-29.14-33.74-27.26-8.72
Income Taxes0.170.120.010.020.020.010.16
Consolidated Net Income-92.57-42.63-31.75-29.16-33.76-27.27-8.88
Net Income From Continuing Operations-92.57-42.63-31.75-29.16-33.76-27.27-8.88
Net Income-92.57-42.63-31.75-29.16-33.76-27.27-8.88
EPS (Recurring)-1.02-0.51-0.46-0.44-0.49-0.67-0.22
EPS (Basic, Before Extraordinaries)-1.04-0.53-0.45-0.42-0.53-0.67-0.22
EPS (Diluted)-1.04-0.53-0.45-0.42-0.53-0.67-0.22
EBITDA--41.06-34.94-34.61-31.16-13.01-9.16
Non-Operating Income (Expense)-0.532.224.384.542.20-0.200.74
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense-8.397.836.265.330.590.44
Shares Outstanding92.3388.0170.3869.6769.1140.5340.43
Market Capitalization1,266.951,266.95216.76209.11219.46337.56338.59

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other13.7813.3112.6010.739.659.3110.278.29
Research and Development9.9110.979.588.317.017.177.536.17
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-13.78-13.31-12.60-10.73-9.65-9.31-10.27-8.29
Interest Expense31.809.64------
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-45.58-22.95-12.17-11.69-10.05-8.59-9.47-6.92
Income Taxes0.23-0.01-0.04-0.010.070.100.000.00
Consolidated Net Income-45.81-22.94-12.14-11.69-10.11-8.69-9.48-6.92
Net Income From Continuing Operations-45.81-22.94-12.14-11.69-10.11-8.69-9.48-6.92
Net Income-45.81-22.94-12.14-11.69-10.11-8.69-9.48-6.92
EPS (Recurring)-0.51-0.26-0.14-0.14-0.13-0.12-0.14-0.10
EPS (Basic, Before Extraordinaries)-0.51-0.26-0.14-0.14-0.13-0.12-0.14-0.10
EPS (Diluted)-0.51-0.26-0.14-0.14-0.13-0.12-0.14-0.10
EBITDA------9.31--
Non-Operating Income (Expense)0.000.000.43-0.96-0.400.720.801.37
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Shares Outstanding92.3390.1888.0185.2685.0470.5170.3870.05
Market Capitalization1,266.95622.23422.06382.00264.26176.66216.76166.42

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments76.9062.8584.94105.3823.8516.17
Short Term Receivables0.040.020.020.030.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.361.360.801.068.7931.28
Total Current Assets78.3064.2385.76106.4832.6447.45
Net Property, Plant & Equipment26.8821.5421.1613.287.555.39
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets0.93-----
Other Assets0.480.430.470.392.030.14
Total Assets106.5886.20107.39120.1542.2252.99
Short Term Debt Incl. Current Port. of LT Debt1.131.011.060.670.000.00
Accounts Payable3.873.532.571.421.200.96
Other Current Liabilities5.514.133.472.253.201.12
Total Current Liabilities10.518.687.104.344.412.09
Long Term Debt12.6011.5312.214.5253.9653.96
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities1.02-----
Other Liabilities5.353.343.605.6318.625.37
Total Liabilities29.4823.5422.9114.4976.9961.42
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity77.1062.6784.47105.66-34.78-8.43
Total Shareholders Equity77.1062.6784.47105.66-34.78-8.43
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity77.1062.6784.47105.66-34.78-8.43
Total Liabilities & Stockholders Equity106.5886.20107.39120.1542.2252.99
Book Value Per Share0.880.891.211.53-0.86-0.21
Tangible Book Value Per Share0.880.891.211.53-0.86-0.21
Full-Time Employees11211212194832
Price to Book Ratio28.713.132.332.05-11.441.35
Return on Assets-44.22-32.80-25.63-41.59-128.70-
Return on Equity-61.00-43.16-30.67-95.27--
Return on Invested Capital-47.52-42.79-30.16-30.64-142.13-19.51
Quick Ratio7.457.4012.0724.557.4122.73
Current Ratio7.457.4012.0724.557.4122.73

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income--42.63-31.75-29.16-33.76-27.27-8.88
Depreciation-1.231.101.070.980.780.09
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00
Other Funds (Non Cash)-12.429.707.639.2114.100.65
Funds from Operations--28.97-20.95-20.45-23.57-12.40-8.15
Extraordinary Item-0.000.000.000.000.000.00
Changes in Working Capital-2.291.172.49-0.310.580.90
Income Taxes Payable-0.10-----
Cash from Operating Activities--26.68-19.78-17.96-23.88-11.81-7.25
Capital Expenditures--6.08-2.24-6.40-0.90-2.93-3.77
Net Assets From Acquisitions-0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.000.000.000.000.000.00
Purchase or Sale of Investments--14.5123.110.000.000.000.00
Purchase of Investments--70.49-125.080.000.000.000.00
Sale Or Maturity of Investments-55.98148.190.000.000.000.00
Other Uses-0.00-0.10-166.78-121.14-8.08-70.20
Other Sources-0.000.00191.8632.1030.2866.15
Cash from Investing Activities--20.5920.7718.68-89.9419.27-7.82
Cash Dividends Paid-0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00
Change in Capital Stock-45.770.030.053.360.1129.32
Repurchase of Common Pref Stock-0.000.000.000.000.000.00
Sale of Common Pref Stock-45.770.030.053.360.1129.32
Proceedsfrom Stock Options-0.000.000.000.000.0028.73
Issuance or Reduction of Debt, Net-0.000.000.000.000.000.00
Change in Long Term Debt-0.000.000.000.000.000.00
Issuance of Long Term Debt-0.000.000.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.000.005.2593.540.000.00
Other Financing Activities Uses-0.000.000.000.000.000.00
Cash from Financing Activities-45.770.035.3096.910.1129.32
Exchange Rate Effect--0.020.06-0.05-0.260.110.08
Net Change in Cash--1.521.075.97-17.177.6814.33
Free Cash Flow--32.76-22.02-24.36-24.78-14.74-11.02

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments104.7780.2376.9075.8883.2554.85
Short Term Receivables0.000.000.040.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.061.121.361.222.521.94
Total Current Assets106.8381.3578.3077.1085.7856.79
Net Property, Plant & Equipment26.8926.9626.8827.1224.7123.70
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets--0.93---
Other Assets0.530.460.480.470.460.44
Total Assets134.25108.77106.58104.69110.9580.93
Short Term Debt Incl. Current Port. of LT Debt1.321.201.131.121.081.00
Accounts Payable3.173.723.873.062.402.58
Other Current Liabilities5.155.535.514.974.686.19
Total Current Liabilities9.6310.4510.519.148.169.77
Long Term Debt13.8413.1412.6012.3812.2311.29
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.310.091.020.150.16-
Other Liabilities66.4215.755.355.433.783.54
Total Liabilities90.1939.4229.4827.1124.3324.60
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity44.0569.3577.1077.5886.6256.33
Total Shareholders Equity44.0569.3577.1077.5886.6256.33
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity44.0569.3577.1077.5886.6256.33
Total Liabilities & Stockholders Equity134.25108.77106.58104.69110.9580.93
Book Value Per Share0.480.770.880.911.020.80
Tangible Book Value Per Share0.480.770.880.911.020.80
Full-Time Employees--112---
Price to Book Ratio28.718.075.444.433.912.82
Return on Assets-75.51-59.96-44.22-40.90-34.01-35.40
Return on Equity-141.68-90.51-61.00-54.38-43.83-47.95
Return on Invested Capital-79.14-27.81-13.53-12.99-10.23-12.85
Quick Ratio11.097.797.458.4310.525.81
Current Ratio11.097.797.458.4310.525.81

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.29%3.9M74.2M525.87K
2026-10-154.63%3.4M74.2M557.90K
2026-09-304.68%3.4M73.7M623.31K
2026-09-154.72%3.5M73.7M666.14K
2026-08-314.32%3.1M71.5M785.35K
2026-08-144.28%3.1M71.5M818.24K
2026-07-314.49%3.2M71.5M931.62K
2026-07-154.28%3.0M69.7M882.53K
2026-06-303.17%2.2M69.7M781.21K
2026-06-153.02%2.1M69.6M682.80K
2026-05-292.57%1.8M69.6M529.51K
2026-05-152.13%1.5M69.6M446.29K
2026-04-301.46%1.0M69.6M289.89K
2026-04-151.31%0.9M69.6M301.67K
2026-03-311.30%0.8M59.2M355.04K
2026-03-130.97%0.6M59.2M339.85K
2026-02-271.04%0.6M57.4M356.28K
2026-02-131.14%0.7M57.4M315.32K
2026-01-301.15%0.7M57.4M276.85K
2026-01-150.92%0.5M57.4M216.37K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5010.4012.8010.3312.8964.000.000.992-0.0170.001
call5.008.309.809.306.4773.001.000.976-0.0280.001
call7.505.807.705.954.9202.000.000.963-0.0270.002
call10.003.504.803.602.8234170.000.939-0.0240.003
call12.501.952.102.001.2828106.000.772-0.0480.007
call15.000.550.700.551.1721,0031230.422-0.0610.009
call17.500.100.350.101.4727683940.211-0.0530.006
call20.000.000.200.101.69379311.000.121-0.0420.004
call22.500.000.600.302.07870.000.000.104-0.0470.004
call25.000.000.050.251.8521100.000.034-0.0160.002
put2.500.000.050.345.4024.000.00-0.009-0.0150.001
put5.000.000.750.304.0111930.00-0.024-0.0280.001
put7.500.000.750.072.6071550.00-0.037-0.0260.002
put10.000.050.100.051.569729603-0.061-0.0230.003
put12.500.200.400.271.24110,1053.00-0.228-0.0460.007
put15.001.001.801.501.48959.000.00-0.578-0.0590.009
put17.502.804.000.001.9350.000.00-0.789-0.0510.006
put20.005.206.700.002.7860.000.00-0.879-0.0400.004
put22.507.709.200.003.3300.000.00-0.896-0.0440.004
put25.0010.2011.700.003.8360.000.00-0.966-0.0150.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-29SEC
2026-10-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-22SEC
2026-10-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-19SEC
2026-08-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-31SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-10SEC
2026-07-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-21SEC
2026-07-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-15SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-06144Filing for proposed sale of securities under Rule 144.SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-02144Filing for proposed sale of securities under Rule 144.SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-30144Filing for proposed sale of securities under Rule 144.SEC
2026-06-26144Filing for proposed sale of securities under Rule 144.SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-25SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-23144Filing for proposed sale of securities under Rule 144.SEC
2026-06-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-23SEC
2026-06-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-11SEC
2026-06-04144Filing for proposed sale of securities under Rule 144.SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-03SEC
2026-06-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-01SEC
2026-05-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0800291.35K2
2026-0700291.87K3
2026-0600979.21K4
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Gem Investment Advisors, LLC1.63%
UBS Group AG1.36%
HighTower Advisors, LLC0.97%
BOOTHBAY FUND MANAGEMENT, LLC0.88%
Aquamarine Financial0.82%
Pier Capital, LLC0.79%
Apella Capital, LLC0.41%
ARK Investment Management LLC0.31%
POLEN CAPITAL MANAGEMENT LLC0.25%
Focus Partners Wealth0.21%

Funds

Fund% owned
ARK Israel Innovative Technology ETF0.21%
Adara Smaller Companies Fund0.15%
Dunham Small Cap Growth Fund0.08%
Even Herd Long Short ETF0.03%
Avantis Responsible International Equity ETF0.01%
Avantis International Equity Fund0.00%
Goldman Sachs MSCI World Private Equity Return Tracker ETF0.00%

OakChart. DRTS. Cached 15 minutes.